No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 379 | 422 | 542 | 541 | 554 | 562 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 20 | 28 | 30 | 35 | 54 | 63 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, the NAFTA region, and other international markets. Its business is organized into three primary divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The diverse product portfolio includes prominent dietary supplements such as Creapure® and Alipure®, along with the creatine-based LIVADUR®. For animal nutrition, AlzChem supplies Creamino®, a guanidinoacetic acid preparation. The pharmaceutical industry benefits from its Bioselect® brand. Industrial applications feature DYHARD® curing agents, acting as accelerators in adhesives, powder coatings, printed circuit boards, and composites, while SILZOT® silicon nitride is vital for ceramics, electronics, and solar technology. The company also manufactures a variety of fine and foundational chemicals, encompassing products derived from calcium carbide, calcium cyanamide (marketed as PERLKA®), hydrogen cyanamide, dicyandiamide, guanidine, guanamines, nitroguanidine, and various aromatic and aliphatic nitriles. Its agricultural offerings include ALZOGUR® germicide for pig pens, Dormex® and Sitofex® plant growth regulators, and BREAK-THRU® plant protection additives. Furthermore, AlzChem provides crucial products for hot metal desulfurization and secondary metallurgy, in addition to technical gases. Beyond its core chemical activities, the group also oversees chemical park operations, offers administrative assistance, and delivers a range of infrastructure services. Established in 1908, AlzChem Group AG maintains its headquarters in Trostberg, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, the NAFTA region, and other international markets. Its business is organized into three primary divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The diverse product portfolio includes prominent dietary supplements such as Creapure® and Alipure®, along with the creatine-based LIVADUR®. For animal nutrition, AlzChem supplies Creamino®, a guanidinoacetic acid preparation. The pharmaceutical industry benefits from its Bioselect® brand. Industrial applications feature DYHARD® curing agents, acting as accelerators in adhesives, powder coatings, printed circuit boards, and composites, while SILZOT® silicon nitride is vital for ceramics, electronics, and solar technology. The company also manufactures a variety of fine and foundational chemicals, encompassing products derived from calcium carbide, calcium cyanamide (marketed as PERLKA®), hydrogen cyanamide, dicyandiamide, guanidine, guanamines, nitroguanidine, and various aromatic and aliphatic nitriles. Its agricultural offerings include ALZOGUR® germicide for pig pens, Dormex® and Sitofex® plant growth regulators, and BREAK-THRU® plant protection additives. Furthermore, AlzChem provides crucial products for hot metal desulfurization and secondary metallurgy, in addition to technical gases. Beyond its core chemical activities, the group also oversees chemical park operations, offers administrative assistance, and delivers a range of infrastructure services. Established in 1908, AlzChem Group AG maintains its headquarters in Trostberg, Germany.